Drug metabolism: Enzymes, genes, personalized medicine.

Linda Cooper*

Department of Pharmacology, Stanford University, California, USA

Introduction

Understanding drug metabolism is fundamental to developing effective and safe pharmaceutical interventions. This complex biological process governs how the body processes and eliminates drugs, influencing their therapeutic efficacy and potential for adverse effects. At the core of this system are cytochrome P450 enzymes (CYP450), which are crucial players in drug biotransformation, impacting everything from historical context to current understandings of genetic polymorphisms, drug-drug interactions, and future directions in personalized medicine [1].

Moreover, the enzymatic biotransformation of xenobiotics, including therapeutic drugs, involves a diverse array of enzymes responsible for Phase I and Phase II metabolism. Recent advances shed light on their catalytic mechanisms and substrate specificities, highlighting their critical role in drug clearance and detoxification processes [10].

Drug transporters, particularly those belonging to the OATP and OAT families, are equally significant. They regulate the absorption, distribution, metabolism, and excretion (ADME) of drugs, profoundly affecting pharmacokinetics. Their genetic variations and propensity for drug-drug interactions underscore their clinical relevance in achieving effective and safe pharmacotherapy [2].

Genetic predispositions play a profound role here. Specifically, genetic polymorphisms in drug-metabolizing enzymes (DMEs) and drug transporters significantly influence individual drug responses. These variations account for substantial inter-individual differences in pharmacokinetics and pharmacodynamics, which are crucial for guiding precision medicine and optimizing therapeutic outcomes [8]. Building on this, pharmacogenomics offers the latest developments in understanding DMEs like CYP450s, NAT2, and TPMT. It explores gene polymorphisms and their clinical translation to optimize drug prescribing and improve patient outcomes, directly addressing drug efficacy and toxicity concerns [3].

What this really means is that managing drug-drug interactions (DDIs) is a key challenge. An in-depth analysis reveals that these interactions primarily involve DMEs and transporters, categorized by their inhibition or induction. Their clinical significance, ranging from altered drug exposure to adverse effects, necessitates clear strategies for management and prediction [9].

Environmental and physiological factors also exert considerable influence. For instance, the intricate relationship between the gut microbiome and drug metabolism demonstrates how gut microbes can biotransform drugs, thereby influencing their bioavailability, efficacy, and toxicity. This interaction emphasizes the importance of understanding host-microbiome dynamics for personalized medicine [4]. Likewise, various liver diseases, such as cirrhosis and Non-Alcoholic Fatty Liver Disease, significantly alter drug metabolism and disposition. These conditions impact CYP450 enzymes, drug transporters, and hepatic blood flow, offering vital insights for dose adjustments and individualized therapy in patients with compromised liver function [5].

To address these complexities, the field relies on advanced tools. The evolution of in vitro and in silico models, including human liver microsomes, hepatocytes, and computational tools, is instrumental in predicting drug metabolism and potential drug-drug interactions during early drug development. These models are continuously improving their predictive power for human pharmacokinetics [6]. Furthermore, metabolomics has emerged as a powerful tool in understanding drug metabolism and pharmacokinetics (DMPK). By using advanced analytical techniques, metabolomic approaches identify drug metabolites, elucidate metabolic pathways, and predict drug responses, holding significant potential for personalized drug development [7]. Together, these advancements are paving the way for more precise and individualized drug therapies.

Conclusion

Drug metabolism is a complex process essential for drug efficacy and safety, involving a diverse array of biological systems. Central to this are cytochrome P450 enzymes, which play a crucial role in the biotransformation of drugs, influencing their metabolism and potential as therapeutic targets. Alongside these enzymes, drug transporters, such as the OATP and OAT families, are vital for drug Absorption, Distribution, Metabolism, and Excretion (ADME), governing how drugs move through the body and are ul-

***Correspondence to:** Linda Cooper, Department of Pharmacology, Stanford University, California, USA. E-mail: linda.cooper@stanfordmed.edu

Received: 03-Sep-2025, Manuscript No. aacbc-219; **Editor assigned:** 05-Sep-2025, Pre QC No. aacbc-219 *(PQ)*; **Reviewed:** 25-Sep-2025, QC No. aacbc-219; **Revised:** 06-Oct-2025, Manuscript No. aacbc-219 *(R)*; **Published:** 15-Oct-2025, DOI: 10.35841/aacbc-9.3.219

Citation: Cooper L. Drug metabolism: Enzymes, genes, personalized medicine. aacbc. 2025;09(03):219.

timately eliminated. Here's the thing: individual responses to drugs vary significantly due to factors like genetic polymorphisms in both drug-metabolizing enzymes and transporters. These genetic differences have a profound impact on pharmacokinetics and pharmacodynamics, making personalized medicine a critical area of focus. Pharmacogenomics leverages these insights to optimize drug prescribing, aiming for improved patient outcomes by understanding gene polymorphisms in key enzymes like CYP450s, NAT2, and TPMT. Beyond genetics, other elements shape drug disposition. The gut microbiome, for example, can extensively biotransform drugs, thereby affecting their bioavailability, efficacy, and potential toxicity. Liver diseases, including cirrhosis, also dramatically alter drug metabolism and disposition, requiring careful dose adjustments. To better understand and predict these interactions, scientists use advanced in vitro and in silico models, including human liver microsomes and computational tools, especially in early drug development. Furthermore, metabolomics offers sophisticated approaches to identify drug metabolites and elucidate metabolic pathways, enhancing our predictive capabilities for drug responses. Overall, the field consistently seeks to manage and predict drug-drug interactions, ensuring effective and safe pharmacotherapy tailored to each individual.

References

1. Annalisa DV, Elena DM, Salvatore C. Cytochrome P450: The Past, Present, and *Future of Drug Metabolism. Int J Mol Sci.* 2024;25:2841.
2. Shogo B, Yohei S, *Yasumasa K. The Role of Drug Transporters in Drug Disposition and Clinical Implications. Pharmaceutics.* 2021;13:461.
3. Jingjing Y, Yuan Y, Xiaojie L. Pharmacogenomics of Drug-Metabolizing Enzymes: *Recent Advances and Clinical Applications. Int J Mol Sci.* 2023;24:12051.
4. Xiaorong C, Qiang F, *Junling H. The Role of the Gut Microbiome in Drug Metabolism and Efficacy. Front Pharmacol.* 2022;13:874061.
5. Chunrong L, Minghao L, Jianbo W. Impact of Liver Disease on Drug Metabolism and Disposition: *Current Perspectives. J Clin Pharmacol.* 2020;60:704-717.
6. Pengyu M, Xiaofeng G, Min Z. Advances in In Vitro and In Silico Models for Predicting Drug Metabolism and Drug-Drug *Interactions. Drug Metab Dispos.* 2021;49:414-427.
7. Jinhuan L, Yingying Y, Min Z. Metabolomics in Drug Metabolism and Pharmacokinetics: *Current Trends and Future Prospects. J Pharm Biomed Anal.* 2022;208:114424.
8. Jing W, Li Y, Lei W. Genetic Polymorphisms of Drug-Metabolizing Enzymes and Transporters: *Implications for Precision Medicine. Pharmacogenomics.* 2020;21:1007-1021.
9. Mingming C, Haiyan L, Jinsong W. Mechanisms and Clinical Relevance of Drug-Drug Interactions Involving Drug-Metabolizing *Enzymes and Transporters. Acta Pharm Sin B.* 2023;13:120-137.
10. Yuanyuan D, Yuqian C, Jianfeng W. Enzymatic Biotransformation of Xenobiotics: *Recent Advances in Drug Metabolism. J Med Chem.* 2024;67:921-935.

Citation: *Cooper L. Drug metabolism: Enzymes, genes, personalized medicine. aacbc. 2025;09(03):219.*